Prognostic impact of CD133 expression in Endometrial Cancer Patients
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Mancebo Moreno, Gemmaca
- dc.contributor.author Solé-Sedeño, Josep Mariaca
- dc.contributor.author Pino, O.ca
- dc.contributor.author Miralpeix, Esterca
- dc.contributor.author Mojal, Sergioca
- dc.contributor.author Garrigós, Laiaca
- dc.contributor.author Lloveras Rubio, Belenca
- dc.contributor.author Navarro Medrano, Pilarca
- dc.contributor.author Gibert, Joanca
- dc.contributor.author Lorenzo Perez, Martaca
- dc.contributor.author Aran, Irisca
- dc.contributor.author Carreras Collado, Ramónca
- dc.contributor.author Alameda Quitllet, Franciscoca
- dc.date.accessioned 2018-07-25T06:44:33Z
- dc.date.available 2018-07-25T06:44:33Z
- dc.date.issued 2017
- dc.description.abstract To assess the impact of CD133 expression on the prognosis of endometrioid endometrial carcinoma (EEC). We retrospectively assessed CD133 expression in tissue microarray of 116 surgically treated FIGO I-III EEC. Tumors with ≥10% of CD133-expressing cells were considered CD133-positive (CD133+). On the basis of CD133 expression, clinical and pathological parameters, progression-free survival (PFS) and overall survival (OS) were evaluated. Of the EEC studied 85.2% showed CD133-expressing cells. Only 61% (n = 66) of EEC presented ≥10% of CD133 expressing cells and were considered CD133+. The mean OS for CD133+ tumour patients was 161 months (95% CI, 154-168) as compared with 146 months (95% CI, 123-160) for those with CD133- tumors (p = 0.012). The mean PFS for CD133+ tumour was 159 months (95% CI, 149-168) as compared with 147 months (95% CI, 132-161) in those with a CD133-tumour (p = 0.014). CD133+ tumours were less likely to have vascular invasion (p = 0.010) and more likely to be well differentiated (p = 0.034). C133+ tumours predicted favorable OS and PFS of EEC patients, with a Hazard Ratio 4.731 (95% CI, 1.251-17.89; p = 0.022). CD133+ tumor status correlates with favorable prognosis of EEC. Our findings are in agreement with studies addressing brain and colorectal tumours.
- dc.format.mimetype application/pdf
- dc.identifier.citation Mancebo G, Sole-Sedeno JM, Pino O, Miralpeix E, Mojal S, Garrigos L. et al. Prognostic impact of CD133 expression in Endometrial Cancer Patients. Sci Rep. 2017 Aug 9;7(1):7687. DOI: 10.1038/s41598-017-08048-0
- dc.identifier.doi http://dx.doi.org/10.1038/s41598-017-08048-0
- dc.identifier.issn 2045-2322
- dc.identifier.uri http://hdl.handle.net/10230/35256
- dc.language.iso eng
- dc.publisher Nature Publishing Groupca
- dc.relation.ispartof Scientific Reports. 2017 Aug 9;7(1):7687
- dc.rights Copyright © The Author(s) 2017. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.other Encometri -- Càncer
- dc.title Prognostic impact of CD133 expression in Endometrial Cancer Patientsca
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion